Arcellx, Inc.
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
ACLX | US
Overview
Corporate Details
- ISIN(s):
- US03940C1009
- LEI:
- Country:
- United States of America
- Address:
- 800 BRIDGE PARKWAY, 94065 REDWOOD CITY
- Website:
- https://www.arcellx.com/
- Sector:
- Manufacturing
Description
Arcellx, Inc. is a clinical-stage biotechnology company that develops immunotherapies for patients with cancer and autoimmune diseases. The company is focused on reimagining cell therapy through its proprietary D-Domain technology. This technology is the foundation for its two main platforms: ddCAR, which produces autologous and allogeneic CAR-T therapies, and ARC-SparX, which involves controllable and adaptable cell therapies. Arcellx's lead investigational product, CART-ddBCMA, is in clinical development for the treatment of relapsed or refractory multiple myeloma. The company aims to create therapies that are safer, more effective, and more broadly accessible.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Arcellx, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Arcellx, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Arcellx, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
